Scientist, Bioanalytical – Drug Antibody Conjugates (DACs)

Nurix Therapeutics; Brisbane (CA); On-site; USD 90,000 - 130,000; Full time

Job summary

Nurix Therapeutics seeks a Scientist to lead bioanalytical strategies for next-generation degrader antibody conjugates (DACs). The role emphasizes LC-MS/MS and hybrid assays to analyze bioconjugates across in vitro and in vivo studies, shaping understanding of pharmacokinetics, pharmacodynamics and biotransformation.

The candidate will work at the interface of small and large molecule bioanalysis, contribute to assay development and method qualification, and collaborate with discovery and early

Qualifications

• Experience leading LC-MS/MS bioanalytical assays.
• In vitro and in vivo study support.
• Assay development and qualification.

Responsibilities

• Lead bioanalytical strategies for DACs.
• Develop and qualify LC-MS/MS and hybrid assays.
• Characterize pharmacokinetics, pharmacodynamics, and biotransformation.
• Collaborate across discovery and development teams.

Skills

LC-MS/MS

Hybrid assays

Bioanalysis

Pharmacokinetics

Tools

Mass spectrometry

Job description

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix Therapeutics is seeking a Scientist to lead bioanalytical strategies supporting the discovery and development of next-generation degrader antibody conjugates (DACs). This role will focus on LC-MS/MS and hybrid assay strategies for quantitative and qualitative analysis of complex bioconjugates across in vitro and in vivo studies to understand DAC pharmacokinetics, pharmacodynamics, and biotransformation. The successful candidate will operate at the interface of small and large molecule bioanalysis, and will contribute to assay development, method qualification, and execution, applying advanced LC-MS/MS and hybrid approaches to support in vitro and in vivo studies across discovery and early development